Fed Governor Cook sues Trump over firing attempt
NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a company specializing in oncology and obesity treatments with a market capitalization of approximately $71 million, has initiated the first phase of a clinical trial for its obesity drug CRB-913. This trial, which involves single and multiple ascending doses, started this week with the first subject being dosed. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet, and a healthy current ratio of 12.9x.
CRB-913 is a second-generation cannabinoid type-1 (CB1) receptor inverse agonist. Unlike its predecessors, such as rimonabant, which were abandoned due to neuropsychiatric side effects, CRB-913 is designed to be more peripherally restricted, potentially reducing central nervous system penetration and associated risks.
Pre-clinical data presented at Obesity Week 2024 showed that CRB-913 is significantly more peripherally restricted than both monlunabant and rimonabant. In particular, CRB-913 has a brain-to-plasma ratio fifty times lower than rimonabant, and it is fifteen times more peripherally restricted than monlunabant, suggesting a safer profile for human use. The stock, currently trading near its 52-week low of $5.65, has caught analysts’ attention, with price targets ranging from $35 to $73 per share. InvestingPro analysis suggests the stock is currently undervalued based on its Fair Value assessment.
The current Phase 1 trial is set to conclude in Q3 2025, with a Phase 1b dose-range finding study slated to begin in Q4 2025 and completion expected in the second half of 2026. Corbus’s CEO, Yuval Cohen, Ph.D., expressed optimism about the drug’s potential for treating obesity through an oral small molecule, highlighting the possibility of using CRB-913 as monotherapy, in combination with incretin analogs, or as a maintenance therapy following incretin analog induction.
Corbus’s diversified portfolio also includes CRB-701, a targeted cancer therapy, and CRB-601, an anti-integrin monoclonal antibody. The company, headquartered in Norwood, Massachusetts, aims to address serious illnesses by leveraging scientific approaches to well-understood biological pathways. While the company’s financial health score from InvestingPro is rated as "FAIR," investors should note that three analysts have recently revised their earnings expectations upward for the upcoming period. For comprehensive analysis and 12 additional ProTips about CRBP, including detailed financial metrics and expert insights, consider accessing the full Pro Research Report available on InvestingPro.
The information in this article is based on a press release statement from Corbus Pharmaceuticals Holdings, Inc. The forward-looking statements in the press release reflect the company’s expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Investors are advised to exercise caution and not place undue reliance on these forward-looking statements.
In other recent news, Corbus Pharmaceuticals has announced several key developments. The company appointed Ian Hodgson as the new Chief Operating Officer, effective last Friday, as detailed in a recent SEC filing. Hodgson, previously the Head of Operations, brings over 25 years of experience in drug development and operations. In another update, H.C. Wainwright adjusted its price target for Corbus Pharmaceuticals from $75 to $50, while maintaining a Buy rating. The analyst noted the company’s ongoing progress with CRB-701, presented at the ASCO GU 2025 event, showing promise in treating multiple solid tumors. William Blair also initiated coverage of Corbus with an Outperform rating, citing the potential of CRB-701 due to its extended half-life and improved linker stability. Additionally, Corbus Pharmaceuticals announced that Dr. Peter Salzmann will not seek re-election to the Board of Directors, resulting in a reduction of board members from eight to seven after the 2025 annual meeting. These developments reflect Corbus’s strategic moves and ongoing research efforts in the competitive pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.